At a time when it matters most, UK-based KSG Health Ltd. are making safe air a reality. Recognising the current concern surrounding virus transmission, they are providing a real solution for those challenged with the control of COVID-19 and other airborne risks within various sectors, including healthcare, education and general commerce.
As an importer and distributor of Genano Ltd air purification devices in the UK, KSG Health Ltd have seen first-hand how this innovative technology allows building owners and managers to remove ultrafine particles effectively and efficiently and produce clinically clean air.
Genano, a Finland born company, has developed a unique air decontamination method that removes and kills even nano-sized particles up to 0.003 µm (3 nm) size from the indoor air. This includes the elimination of microbes, such as viruses, bacteria and moulds, and removes also gases and odours.
At present, healthcare authorities combatting the outbreak of COVID-19 are upgrading their medical infrastructure, due to traditional air purification methods not being enough to contain the icroorganisms in the air. The commonly used fibre HEPA filters are deemed to be powerless against the microbes that are less than 0.3 µm in size, and unfortunately, the COVID-19 microbes are slightly larger than 0.1 µm size.
This means that air purification technologies based on HEPA filtration are unable to remove tiny, problematic particles - including pollution, microbes, bacteria, and viruses - so there is a potential for these to remain in the recirculated air, be inhaled and expose building users to serious illness. Additionally, HEPA filters can become dirty from the collected particles and their air purification performance is reduced and, because of not killing the particles, the used filters are clinical waste for special and expensive disposal.
What’s more, since Genano technology is based on electronic filtration there is no contaminated residue left behind to re-infect the passing airstream. A powerful ionisation process takes place within the chamber which is efficiently flushed out on a weekly basis without any reduction in performance. With no toxic waste being produced and minimal maintenance requirements, these units are efficient, cost-effective and ideally suited to every indoor environment.
Speed and capacity are important factors when it comes to constantly maintaining a high-quality air supply and KSG Health’s Genano devices have these needs covered too. Genano devices even have an additional carbon filtration stage which removes VOC gases e.g. odours from the already particle free air, resulting in perfectly pure indoor air.
Whilst Genano technology is innovative, it is not new; it has been protecting the health and well-being of building occupants for 20 years. It is already installed in thousands of schools, hospitals, laboratories and offices around the world, and KSG Health are extending the long list of reassured clients here in the UK.
Jarmo Kesanto, Co-Founder and Co-Director of KSG Health Ltd explains:
“Our well-established technology is ideally suited to meet the challenges posed by airborne viruses and we are eager to see it utilised in all key settings to enhance the protection of vulnerable people.
We hope that more organisations, including the NHS, will soon realise the benefits of replacing their current systems. Sadly, when it comes to nanosized particles such as SARS MERS and COVID-19, the more limited HEPA-based systems are insufficient to remove these from the circulating air. At such a critical time, that may simply not be good enough.
It is our mission to demonstrate how Genano represents the next step in infection control and add to the scores of existing customers who benefit daily from the peace of mind and cost-effectiveness these innovative systems offer.”